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Objectives The purpose of this study was to evaluate the effect of low dose doxycycline and atorvastatin on gingival inflammation and 
alveolar bone loss in an experimental model of periodontitis in rats.
Methods Forty male Sprague Dawley rats were divided into four study groups as follows: (I) experimental periodontitis control, (II) rats with 
periodontitis treated with low dose atorvastatin (10 mg/kg), (III) rats with periodontitis treated with low dose doxycycline (6 mg/kg) and 
rats with periodontitis treated with both doxycycline and atorvastatin. Periodontitis was induced by ligature placement around the upper 
left second molar foe seven days. The periodontitis group received saline, periodontitis/doxycycline group received doxycycline by oral 
gavage, periodontitis/atorvastatin group received atorvastatin by oral gavage and doxycycline/atorvastatin group received both drugs 
simultaneously (6 and 10 mg/kg, respectively) for 21 days after ligature placement. Then, the rats were sacrificed and their maxillae were 
removed, defleshed, and prepared for histopathological examination. Data were analyzed statistically by the Kruskal-Wallis test and Mann-
Whitney U test at 5% level of significance and presented as frequency.
Results Using a combination of doxycycline and atorvastatin caused a significant decrease in gingival inflammation and alveolar bone loss 
(16.5%) and collagen degradation (13%) when compared to the control group (36.10% and 36.95%, respectively; P < 0.001).
Conclusion Low dose atorvastatin and low dose doxycycline synergically prevented alveolar bone loss and collagen degradation in ligature-
induced periodontitis in rats.
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Introduction
Periodontitis is a common clinical disorder of the  periodontium 
in adults1 characterized by the loss of connective tissue (CT) 
and alveolar bone loss around the teeth.2,3 It is also  characterized 
by an acute immune response causing the production of 
cytokines, prostaglandins and matrix metalloproteinase as 
well as immune-inflammatory process regulators. Periodontal 
disease is one of the oral problems that has an extensive effect 
on the human population, and is one of the major causes of 
adult tooth loss.4
Oral bacteria and their products (e.g. lipopolysaccharides 
and proteases) are responsible for the initiation of  periodontitis. 
Conversely, the progression of periodontitis depends on the 
host responses to bacterial pathogens. It has been observed 
that the invading bacteria trigger the release of cytokines such 
as interleukin-1 and tumor necrosis factor-α.
Antibiotics have been shown to be helpful in periodontal 
treatment.5 Tetracyclines including doxycycline have long been 
recognized as adjunctive antibiotics for periodontal  treatment 
because of their effectiveness on Gram-negative anaerobic 
 periodontal pathogens, such as Aggregatibacter actinomycetem-
comitans, which is commonly found in the subgingival plaque. 
Although initially it is attributed to their antimicrobial 
properties,6 the clinical efficacy of tetracyclines in periodon-
titis has been recently suggested to be attributed to their 
intrinsic anti-inflammatory activity.7 It has been approved by 
the US Food and Drug Administration and other national 
regulatory agencies in Canada and Europe that the novel ‘‘low 
dose’’ or non-antibacterial formulations of tetracyclines, such 
as low dose doxycycline (LDD) can be used as an adjunctive 
treatment for periodontal disease. Several studies have shown 
that LDD suppresses host-derived matrix metalloproteinases 
in periodontal lesions and thereby inhibits the pathological 
degradation of various collagens, including types I, III, and IV; 
while it preserves other constituents of the periodontal tissues 
(fibronectin, proteoglycan ground substance, elastin, and base-
ment membrane) and inhibits bone resorption.8–11
Atorvastatin is a member of the statin class of inhibitors. 
Through the inhibition of 3-hydroxy-3-methylglutaryl-coen-
zyme A (HMG-CoA) reductase, statins have revolutionized 
the treatment of hypercholesterolemia. The beneficial effects 
of HMGCoA reductase inhibitors are attributed to their ability 
to reduce endogenous cholesterol synthesis.12
Atorvastatin is also used to inhibit metalloproteinase,13 
osteoclastogenesis and bone destruction, as well as the expres-
sion of the receptor activator of nuclear factorkappa B(NF-κβ) 
ligand.14,15 It is yet unknown whether atorvastatin would be 
beneficial in a complex tissue such as the periodontium. In 
addition to bleeding, statins are responsible for a variety of 
biochemical alterations, including reduced accumulation of 
esterified cholesterol in macrophages, an increase in endothe-
lial nitric oxide synthase, reduction of inflammatory processes, 
and increased stability of atherosclerotic plaques. Statin 
therapy is essential for primary and secondary prevention of 
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coronary artery disease.1 Recent experimental and clinical 
 evidence suggests that the beneficial effects of statins may 
extend beyond their cholesterol-lowering effects, to include 
the so-called pleiotropic effects.16 Since the first report by 
Mundy et al,17 in 1999, several statins have shown anabolic 
effects on bone metabolism.18
Statins stimulate osteoblastic differentiation by increasing 
the gene expression of bone morphogenetic protein 2 
(BMP-2).19 They may also increase bone formation by inhib-
iting  osteoblast apoptosis.18 With constant remodeling of bone, 
which includes bone formation and resorption, it is  contributed 
the inhibition of osteoclast activity to the bone preservation. It 
has been reported that statins decrease the osteoclastic activity 
through the RANK-reactive oxygen species pathway.20,21
The aim of the present study was to assess the combined 
effects of low dose atorvastatin and low dose doxycycline for 
treatment of periodontal disease by assessing gingival inflam-
mation, alveolar bone loss and collagen degradation in rats 
with induced periodontitis.
Methods
In this animal study, 40 adult male Sprague-Dawley rats with 
an initial mean weight of 250 to 300 g were used. Ten rats were 
housed in each cage and maintained under a 12-hour light/
dark cycle at a temperature of 22ºC and relative humidity of 
50% with access to standard rat chow pellets (Behparvar Com-
pany, Shiraz, Iran). The nutritional composition of the pellets 
consisted of 88% dry matter, 14% crude protein, 10% crude 
ash, 11% crude cellulose, 1.3% to 2.0% calcium, 1% phos-
phorus, 1% NaCl, and 2.6 kcal/g and ad libitum water. 
The Ethics Committee on Animal Experimentation of Shiraz 
University of Medical Sciences, Shiraz, Iran, approved the 
experimental protocol of the present study.
Experimental induction of periodontitis
For induction of periodontitis, general anesthesia was induced 
by intramuscular injection of a combination of 0.1 mL  ketamine 
hydrochloride (50 mg/mL) and 0.05 mL xylazine hydrochlo-
ride (2 g/100 mL) for each 100 g of body weight. Sterile 5–0 
cotton thread ligatures were placed subgingivally around both 
maxillary second molars. The rats were randomly divided into 
four groups of 10 rats each. In group 1, the rats were fed 
 powdered standard chow, and periodontitis was induced.1 In 
group 2 (periodontitis + low dose atorvastatin) the rats were 
fed powdered standard chow, periodontitis was induced and 
they received low dose atorvastatin (10 mg/kg).22 In group 3 
 (periodontitis + low dose doxycycline), the rats were fed 
 powdered standard chow, periodontitis was induced and they 
received low dose doxycycline orally gavaged at 6 mg/kg dose. 
In group 4 (periodontitis + low dose atorvastatin + low dose 
doxycycline), the rats were fed powdered standard chow, peri-
odontitis was induced and they received low dose atorvastatin 
and low dose doxycycline (10 and 6 mg/kg, respectively). 
The dose of doxycycline in rats was calculated according to 
the method described by Ramamurthy et al.23 Low dose 
 doxy cyc line and low dose atorvastatin were  administered 
daily for 21 days, and after that, the rats were sacrificed.
Histological Examination
Histological evaluations were performed on the maxillary 
right molars. The maxillary specimens were fixed in 10% 
formalin for 24 hours at room temperature and decalcified in 
0.1 M ethylenediaminetetraacetic acid solution at 42°C for 10 
days. Decalcification was performed as described by Cho 
et al,24 with slight modification. Then, the specimens were 
 dehydrated using graded alcohol series, cleared in methyl 
 benzoate, and embedded in paraffin. The paraffin blocks were 
serially cut in mesiodistal direction along the long axis of the 
teeth to provide 6 µm-thick longitudinal sections. Care was 
taken to obtain histological sections in which the first and 
second molars, the interproximal alveolar bone crest, and the 
coronal and root pulp chambers were evident. Sections repre-
sentative of each specimen were selected and stained with 
modified Mallory’s connective tissue staining method.25 Serial 
sections containing the first and second molars, in which the 
coronal and root pulp, cemento-enamel junction at the mesial 
side of the second molar, interproximal alveolar bone, and 
connective fiber attachment were clearly visible, were selected 
for histometric analysis.
Gingival inflammation and alveolar bone loss in different 
groups were descriptively scored from 0 to 3:
Score 0: None or small amount of inflammatory cell 
infiltration limited to marginal gingiva. Alveolar bone and 
cementum were intact. 
Score 1: Moderate infiltration of inflammatory cells 
(inflammation of the entire gingiva) with minimal alveolar 
bone loss and cementum loss. 
Score 2: Severe infiltration of inflammatory cells 
 (inflammation of the entire gingiva and periodontal ligament) 
with moderate alveolar bone loss and partial destruction of 
cementum. 
Score 3: Severe infiltration of inflammatory cells,  complete 
destruction of alveolar bone and severe destruction of 
cementum.
Collagen degradation in different groups was evaluated 
descriptively and scored as: normal = 0, mild = 1, moderate = 2 
or severe = 3.
Statistical analyses
Data were analyzed by SPSS version 19.0 (SPSS Inc., IL, USA) 
and presented as mean ± standard deviation. The non- 
parametric Kruskal-Wallis test was applied to determine 
whether there was any significant difference between the 
groups. The Mann-Whitney U test was performed to detect 
the differences in the frequency of each marker between the 
experimental groups. Differences were interpreted as signifi-
cant at P < 0.05.
Results
Combined treatment decreased gingival 
inflammation and alveolar bone loss
The results revealed that gingival inflammation and alveolar 
bone loss significantly decreased after 21 days of treatment 
with 10 mg/kg/day atorvastatin plus 6 mg/kg/day doxycycline 
(16.50% versus 36.10% in periodontitis group).
Atorvastatin and doxycycline alone had a protective effect 
on alveolar bone of rats with periodontitis (16.79% and 
21.18%, respectively compared to the control group); however, 
there was no significant difference between the treatment 
groups (low dose doxycycline, low dose atorvastatin and both) 
(P > 0.05). 
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Tables 1 and 2 shows the results of histopathological 
examination of rats with periodontitis (control group) with 
intense alveolar bone loss, compared to treatment groups.
Combined treatment decreased collagen 
degradation
Rats with periodontitis (36.95%) showed significantly 
higher collagen destruction compared with low dose ator-
vastatin (22.21%), low dose doxycycline (18.67%) or com-
bination of both (13.00%) (P < 0.001). In other words, 
doxycycline and atorvastatin alone were effective but com-
bined administration of both was the most effective in 
reducing collagen degradation when compared with perio-
dontitis control group (P = 0.000), low dose doxycycline (P 
= 0.000) and low dose atorvastatin group (P = 0.001). Figure 
1 shows macroscopic images of alveolar bone loss and col-
lagen degradation in low dose doxycycline, low dose ator-
vastatin and combined group compared to the periodontitis 
control group.
Discussion
Results of the present study showed that combination of low 
dose doxycycline (6 mg/kg) and atorvastatin (10 mg/kg) can 
cause protection against the destruction of alveolar bone and 
collagen in rats with induced periodontitis.
It was also found that atorvastatin and doxycycline alone 
were capable of inhibiting inflammation and bone loss associated 
with collagen degradation, but there was no  significant difference 
between the protective effects of the two drugs.
A significant reduction in alveolar bone resorption and col-
lagen degradation was noted in the experimental  periodontitis 
group after doxycycline administration. 
Doxycycline is one of the most potent and cost-effective anti-
biotics, which has been shown to reduce collagen  degradation.26 
Our results, similar to those of Ozdemir et al,27 and Bezerra et al.11 
showed that low-dose (sub-antimicrobial) doxycycline prevented 
alveolar bone loss at the macroscopic level. Doxycycline is 14 
times stronger than tetracycline and at low concentrations (2, 
5–10 mg per mL) has the ability to inhibit collagenase secreted 
by neutrophils and  Porphyromonas gingivalis. Another mech-
anism suggested for this inhibition by doxycycline is the inhibi-
tion of matrix metalloproteinase and stress oxidative.23
Yagan et al.28 consistent with our study indicated that 
 periodontitis was induced in rats after 7 days of placement of 
cotton ligatures around teeth. Moreover, they reported that 
low-dose doxycycline (6 mg/kg) for 21 days by oral gavage 
prevented periodontal tissue breakdown by inhibiting local 
and systemic oxidative stress. However, unlike our study, they 
investigated the effect of doxycycline on the oxidant and 
anti-oxidant levels in sera and also histologically.
An increase in oxidants and free radicals produced during 
inflammation is one of the mechanisms of tissue pathogenesis. 
It seems that increased serum levels of oxidants and decreased 
antioxidant enzymes promote inflammation and alveolar bone 
loss by activation of pro-inflammatory cytokines such as IL-6, 
interleukin-1 and TNF-α and subsequently acti vated RANKL 
protease enzymes (osteoclast differentiation stimulator).
Our results consistent with those of other studies29–31 
demonstrated the effectiveness of the oral administration of 
atorvastatin to prevent alveolar bone resorption in rats with 
experimental periodontitis.
Table 2. Effect of low dose doxycycline, low dose atorvastatin 
and combination of both on collagen destruction in rats with 
periodontitis
Group Normal Mild Moderate Severe Mean rank
Control1  
(n = 10) 0 10 70 20 36.95
LDA2 (n = 10) 50 41.7 8.3 0 22.21*
LDD3 (n = 10) 66.7 33.3 0 0 18.67*
LDA + LDD4  
(n = 10) 90 10 0 0 13.00*
Data are presented as frequency of 10 or 12 rats for each group by Kruskal-Wal-
lis test and Mann-Whitney test. 1, Periodontitis; 2, Periodontitis + low dose 
atorvastatin; 3, Periodontitis + low dose doxycycline; 4, Periodontitis + low 
dose atorvastatin + low dose doxycycline; *, P < 0.001.
Table 1. Effect of low dose doxycycline, low dose atorvastatin 
and combination of both on alveolar bone loss in rats with 
periodontitis
Group Normal Mild Moderate Severe Mean rank
Control1  
(n = 10) 0 0 30 70 36.10
LDA2 (n = 10) 0 41.7 41.7 16.7 21.18*
LDD3 (n = 10) 0 58.3 41.7 0 16.79*
LDA + LDD4 
(n = 10) 0 60 40 0 16.50*
Data are presented as frequency of 10 or 12 rats in each group by Kruskal-Wallis 
test and Mann-Whitney U test. 1, Periodontitis; 2, Periodontitis + low dose 
atorvastatin; 3, Periodontitis + low dose doxycycline; 4, Periodontitis + low dose 
atorvastatin + low dose doxycycline; *, P < 0.001 compared with periodontitis 
control group.
Fig 1. Clinical characteristics of teeth and periodontal tissue; (A) 
samples of experimental periodontitis showing resorption of the 
alveolar bone in score 3; (B) samples from LDD group with resorp-
tion of the alveolar bone in score 2; (C) samples from LDA group with 
resorption of the alveolar bone in score 1; (D) samples from LDD + 
LDA group with resorption of the alveolar bone in score 1.
A B
C D
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Several authors have reported the successful use of ator-
vastatin for periodontitis, by reducing tooth loss in patients 
with chronic periodontitis,29 minimizing the signs/symptoms 
of inflammation.30
Fentoğlu et al32 reported that atorvastatin decreased 
pro-inflammatory cytokines in addition to lipid factors in 
 periodontal and hyperlipidemia patients. Also, de Araújo 
Júnior et al.33 showed that 10 mg/kg of atorvastatin can reduce 
bone loss, pro-inflammatory cytokines, oxidative stress, and 
expression of extracellular matrix proteins, as well as RANK/
RANKL while it increases osteoprotegerin in male Wistar 
albino rats with periodontitis.
Conclusion
Our result indicated that atorvastatin and doxycycline can 
reduce alveolar bone loss in ligature-induced periodontitis. 
Combination of low dose atorvastatin and doxycycline may 
exert beneficial effects on metabolic and inflammatory 
 conditions in periodontitis. It seems that both drugs play mul-
tifunctional roles in inhibition of experimental periodontitis 
in rats. Hence, synergic use of atorvastatin and doxycycline is 
more efficient. However, further studies are required to find 
out more about the possible side effects.
Acknowledgment
The authors thank the Vice-chancellery of Research of Shiraz 





 1. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G.  
Cholesterol lowering with simvastatin improves prognosis of diabetic 
patients with coronary heart disease: a subgroup analysis of the Scandinavian 
Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614–620.
 2. Armitage GC. Development of a classification system for periodontal diseases 
and conditions. Annals of periodontology. Ann Periodontol. 1999;4:1–6.
 3. de Monès E, Schlaubitz S, Catros S, Fricain JC. Statins and alveolar bone 
resorption: a narrative review of preclinical and clinical studies. Oral Surg 
Oral Med Oral Pathol Oral Radiol. 2015;119:65–73.
 4. Goes P, Lima AP, Melo IM, Rêgo RO, Lima V. Effect of Atorvastatin in 
radiographic density on alveolar bone loss in wistar rats. Braz Dent J. 
2010;21:193–198.
 5. Pantlin L. Is there a role for antibiotics in periodontal treatment? Dent 
update. 2008;35:493–496.
 6. Vernillo A, Rifkin B. Effects of tetracyclines on bone metabolism. Adv Dent 
Res. 1998;12:56–62.
 7. Walker C, Thomas J, Nangó S, Lennon J, Wetzel J, Powala C. Long-term 
treatment with subantimicrobial dose doxycycline exerts no antibacterial 
effect on the subgingival microflora associated with adult periodontitis.  
J Periodontol. 2000;71:1465–1471.
 8. Grevstad HJ. Doxycycline prevents root resorption and alveolar bone loss 
in rats after periodontal surgery. European Journal of Oral Sciences. Scand J 
Dent Res. 1993;101:287–291.
 9. Caton JG, Ciancio SG, Blieden TM, Bradshaw M, Crout RJ, Hefti AF, et al. 
Treatment with subantimicrobial dose doxycycline improves the efficacy of 
scaling and root planing in patients with adult periodontitis. J Periodontol. 
2000;71:521–532.
10. Golub LM, McNamara TF, Ryan ME, Kohut B, Blieden T, Payonk G, et al. 
Adjunctive treatment with subantimicrobial doses of doxycycline: effects on 
gingival fluid collagenase activity and attachment loss in adult periodontitis. 
J Clin Periodontol. 2001;28:146–156.
11. Bezerra M, Brito G, Ribeiro R, Rocha F. Low-dose doxycycline prevents 
inflammatory bone resorption in rats. Braz J Med Biol Res. 2002;35:613–616.
12. LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H. Treating to New 
Targets (TNT) Steering Committee and Investigators. Safety and efficacy 
of atorvastatin-induced very low-density lipoprotein cholesterol levels in 
patients with coronary heart disease (a post hoc analysis of the treating to 
new targets [TNT] study). Am J Cardiol. 2007;100:747–752.
13. Chandrasekar B, Mummidi S, Mahimainathan L, Patel DN, Bailey SR, Imam 
SZ, et al. Interleukin-18-induced human coronary artery smooth muscle 
cell migration is dependent on NF kappaB-and AP-1-mediated matrix 
metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol 
Chem. 2006;281:15099–15109.
14. Franklin RB, Costello LC. Zinc as an anti-tumor agent in prostate cancer and 
in other cancers. Arch Biochem Biophys. 2007;463:211–217.
15. Roux S, Amazit L, Meduri G, Guiochon-Mantel A, Milgrom E, Mariette X. 
RANK (receptor activator of nuclear factor kappa B) and RANK ligand are 
expressed in giant cell tumors of bone. Am J Clin Pathol. 2002;117: 
210–216.
16. Zhou Q, Liao JK. Pleiotropic effects of statins: basic research and clinical 
perspectives. Circ J. 2010;74:818–826.
17. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, et al. Stimulation of 
bone formation in vitro and in rodents by statins. Science. 1999;286: 
1946–1949.
18. Ruan F, Zheng Q, Wang J. Mechanisms of bone anabolism regulated by 
statins. Biosci Rep. 2012;32:511–519.
19. Chen PY, Sun JS, Tsuang YH, Chen MH, Weng PW, Lin FH. Simvastatin 
promotes osteoblast viability and differentiation via Ras/Smad/Erk/BMP-2 
signaling pathway. Nutr Res. 2010;30:191–199.
20. Moon HJ, Kim SE, Yun YP, Hwang YS, Bang JB, Park JH, et al. Simvastatin 
inhibits osteoclast differentiation by scavenging reactive oxygen species. 
Exp Mol Med. 2011;43:605–612.
21. Yamashita M, Otsuka F, Mukai T, Yamanaka R, Otani H, Matsumoto Y, 
et al. Simvastatin inhibits osteoclast differentiation induced by bone 
morphogenetic protein-2 and RANKL through regulating MAPK, AKT and 
Src signaling. Regul Pept. 2010;162:99–108.
22. Tanriverdi HA, Barut A, Sarikaya S. Statins have additive effects to 
vertebral bone mineral density in combination with risedronate in 
hypercholesterolemic postmenopausal women. Eur J Obstet Gynecol 
Reprod Biol. 2005;120:63–68.
23. Ramamurthy NS, Rifkin BR, Greenwald RA, Xu J-w, Liu Y, Turner G, et al. 
Inhibition of matrix metalloproteinase-mediated periodontal bone loss in 
rats: a comparison of 6 chemically modified tetracyclines. J Periodontol. 
2002;73:726–734.
24. Cho A, Suzuki S, Hatakeyama J, Haruyama N, Kulkarni AB. A method for 
rapid demineralization of teeth and bones. Open Dent J. 2010;4: 
223–229.
25. Crossmon G. A modification of Mallory’s connective tissue stain with a 
discussion of the principles involved. Anatom Rec. 1937;69:33–38.
26. McCulloch C, Birek P, Overall C, Aitken S, Lee W, Kulkarni G. Randomized 
controlled trial of doxycycline in prevention of recurrent periodontitis in 
high‐risk patients: antimicrobial activity and collagenase inhibition. J Clin 
Periodontol. 1990;17:616–622. 
27. Özdemir SP, Kurtis B, Tüter G, Bozkurt S, Gültekin SE, Sengüven B, et al. 
Effects of low-dose doxycycline and bisphosphonate clodronate on alveolar 
bone loss and gingival levels of matrix metalloproteinase-9 and interleukin-
1β in rats with diabetes: a histomorphometric and immunohistochemical 
study. J Periodontol. 2012;83:1172–1182.
28. Yagan A, Kesim S, Liman N. Effect of Low-dose doxycycline  on serum oxidative 
status, gingival antioxidant levels, and alveolar bone loss in experimental 
periodontitis in rats. Journal of periodontology. 2014;85:478–489.
29. Lindy O, Suomalainen K, Mäkelä M, Lindy S. Statin use is associated 
with fewer periodontal lesions: a retrospective study. BMC oral health. 
2008;8:16.
30. Cunha-Cruz J, Saver B, Maupome G, Hujoel PP. Statin use and tooth loss in 
chronic periodontitis patients. J Periodontol. 2006;77:1061–1066.
31. Saxlin T, Suominen‐Taipale L, Knuuttila M, Alha P, Ylöstalo P. Dual effect of 
statin medication on the periodontium. J Clin Periodontol. 2009;36:997–1003.
88 Journal Dental School | Vol. 35, No. 3, Summer 2017: 84–88
Effect of low dose doxycycline & atorvastatin on periodontics
Original Article
Masoumi, et al. 
32. Fentoglu O, Kirzioglu F, Ozdem M, Kocak H, Sutcu R, Sert T. Pro inflammatory 
cytokine levels in hyper lipidemic patients with periodontitis after periodontal 
treatment. Oral diseases. 2012;18:299–306.
33. De Araújo Júnior, Souza TO, de Moura LM, Torres KP, de Souza LlB, Alves Mdo 
S. Atorvastatin decreases bone loss, inflammation and oxidative stress in 
experimental periodontitis. PloS one. 2013;10:e75322.
How to cite:
Masoumi S, Andisheh-tadbir A, Firozabadi N, Bahmanpour M, Tanideh N. Histological Comparison of Effectiveness of Low Doses of Doxycyclineand Atorvastatin on gingiva Inflammation and Alveolar 
Bone Loss in Experimental Model of Periodontitis in Rats. J Dent Sch. 2017;35(3):84–88.
